• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACHC alert in real time by email

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno.

    "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth."

    Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:ACHC), a leader in the behavioral healthcare industry, where he drove financial discipline and operational performance across its network. Before Acadia, Young served as EVP and CFO at Elanco (NYSE:ELAN), one of the world's largest independent animal health companies, where he played a central role in establishing the company as an independent public entity following its separation from Eli Lilly.

    "NVA has built something truly special for veterinarians, pet families, and the animals they love," said Young. "I am honored to join and look forward to partnering with John and the team to strengthen the financial foundation that drives continued value creation."

    Young's appointment reflects NVA's continued investments across its care network as the company builds toward its next chapter.

    About NVA

    National Veterinary Associates is defining the future of animal care. NVA is a community of 1,300 care centers across North America, including general practice veterinary hospitals, equine hospitals, pet resorts, and specialty and emergency expertise through Ethos Veterinary Health. For more information, visit www.nva.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260424515030/en/

    Media Contact

    Michelle Reardon

    Michelle.Reardon@nva.com

    Get the next $ACHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHC
    $ELAN

    CompanyDatePrice TargetRatingAnalyst
    Acadia Healthcare Company Inc.
    $ACHC
    6/3/2026$30.00Hold → Buy
    Jefferies
    Acadia Healthcare Company Inc.
    $ACHC
    5/4/2026$39.00Outperform → Strong Buy
    Raymond James
    Elanco Animal Health Incorporated
    $ELAN
    4/15/2026$30.00Buy
    Citigroup
    Acadia Healthcare Company Inc.
    $ACHC
    1/22/2026$15.00Buy → Hold
    Jefferies
    Elanco Animal Health Incorporated
    $ELAN
    1/22/2026Neutral → Overweight
    Piper Sandler
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Acadia Healthcare Company Inc.
    $ACHC
    12/3/2025$14.00Outperform → Market Perform
    Leerink Partners
    Acadia Healthcare Company Inc.
    $ACHC
    12/3/2025$13.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $ACHC
    $ELAN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Elanco Animal Health Incorporated

    SCHEDULE 13G - Elanco Animal Health Inc (0001739104) (Subject)

    7/14/26 1:27:07 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Elanco Animal Health Incorporated

    SD - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:09:19 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:00:57 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Modi Rajeev A. bought $99,939 worth of shares (4,911 units at $20.35), increasing direct ownership by 3% to 160,812 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:39:20 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $99,843 worth of shares (4,971 units at $20.09) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:38:26 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:15:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:15:12 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:14:31 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

    Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro:Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.iKills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.iiAchieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,iiOutlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,iiINDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterin

    7/22/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Healthcare Announces Date for Second Quarter 2026 Earnings Release

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the market. Acadia will host a conference call with institutional investors and analysts on Wednesday, July 29, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the "Investors" section of the website, and the archived webcast will be available after the call has ended.About Acadia HealthcareAcadia is a leading provider of behavioral healthcare services across the United States. As of March 31, 2026, Acadia operated a network of 275 behavioral healthcare facilities with app

    7/9/26 4:15:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/news-events/events-presentation. A replay will also be available on the website shor

    7/8/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Acadia Healthcare upgraded by Jefferies with a new price target

    Jefferies upgraded Acadia Healthcare from Hold to Buy and set a new price target of $30.00

    6/3/26 8:05:16 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare upgraded by Raymond James with a new price target

    Raymond James upgraded Acadia Healthcare from Outperform to Strong Buy and set a new price target of $39.00

    5/4/26 8:30:20 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Elanco Animal Health with a new price target

    Citigroup initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $30.00

    4/15/26 8:08:24 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Acadia Healthcare Appoints David Duckworth as Interim Chief Financial Officer

    Reaffirms Financial Guidance for First Quarter and Full Year 2026 Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced the appointment of David Duckworth, former Chief Financial Officer of Acadia, as Interim Chief Financial Officer, effective May 1, 2026. Duckworth succeeds Todd Young, who is departing from the Company to pursue a CFO role at a private equity-backed animal health company. Young will remain with the Company through April 30, 2026, and will participate in the Company's first quarter earnings call scheduled for the morning of April 30. Debra K. Osteen, Chief Executive Officer of Acadia, said, "We are pleased to welcome David back as Int

    4/23/26 4:15:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Appoints Daniel Cancelmi to Board of Directors

    Wade D. Miquelon to Retire from the Board at Upcoming Annual Meeting Acadia Healthcare Company, Inc. (NASDAQ:ACHC) ("Acadia") today announced that it has appointed Daniel Cancelmi to its Board of Directors, effective immediately. Mr. Cancelmi is a seasoned finance leader with an expansive knowledge of healthcare and a proven track record of driving superior financial performance. Most recently, he served as Executive Vice President and Chief Financial Officer of Tenet Healthcare Corporation, where he played a significant role in the company's transformation and in strengthening its balance sheet. Over the course of his three-decade career at Tenet, he held a range of finance roles of in

    3/12/26 4:15:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $ACHC
    $ELAN
    Financials

    Live finance-specific insights

    View All

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/14/24 1:28:32 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/12/24 9:50:14 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/8/24 10:52:39 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Announces Date for Second Quarter 2026 Earnings Release

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the market. Acadia will host a conference call with institutional investors and analysts on Wednesday, July 29, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the "Investors" section of the website, and the archived webcast will be available after the call has ended.About Acadia HealthcareAcadia is a leading provider of behavioral healthcare services across the United States. As of March 31, 2026, Acadia operated a network of 275 behavioral healthcare facilities with app

    7/9/26 4:15:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/news-events/events-presentation. A replay will also be available on the website shor

    7/8/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports First Quarter 2026 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y

    5/6/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care